Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
So there it was, hanging in the closet. My carefully chosen bridal gown, with its lace in a delicate shade of ivory. Beside it was my bridal veil, featherlight, translucent, and freshly purchased just the day before the wedding. When Anna, my girlfriend, gingerly pinned it on my head, I heard the words of my mother sounding in my head.... Read More
It is with a heavy heart that I pen this follow-up piece on Singapore’s COVID19 situation. In the past few months, the city state has been hailed as an exemplar of early, preemptive and targeted response to combat the pandemic. Other countries have studied its response. As I wrote here on Mar. 19, despite being a densely populated high-risk state,... Read More
A week ago, I wrote an article for Timmerman Report on Singapore’s COVID19 response, and how the country has kept its cases low with no COVID19-related deaths. In that article on Mar. 19, I elaborated on how Singapore had not ordered any businesses to shut down. Instead, the country had kept the number of cases low over the last few... Read More
I was born in Malaysia, but left my family for the promised land of Singapore at the age of 12 under a scholarship program known as the ASEAN program. I lived more than half my life in that country, and have long since become a Singaporean. I currently manage a major Singaporean life sciences VC fund from a San Francisco... Read More